Q2 2018 EPS Estimates for Sol Gel Technologies Ltd (SLGL) Increased by Analyst

Sol Gel Technologies Ltd (NASDAQ:SLGL) – Investment analysts at Jefferies Group increased their Q2 2018 earnings per share estimates for Sol Gel Technologies in a report issued on Wednesday, May 16th. Jefferies Group analyst D. Steinberg now forecasts that the company will earn ($0.46) per share for the quarter, up from their previous estimate of ($0.48). Jefferies Group currently has a “Buy” rating and a $17.00 target price on the stock. Jefferies Group also issued estimates for Sol Gel Technologies’ Q4 2018 earnings at ($0.58) EPS, FY2018 earnings at ($1.99) EPS and FY2020 earnings at ($1.48) EPS.

Other analysts have also recently issued reports about the stock. ValuEngine upgraded shares of Sol Gel Technologies from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. JMP Securities started coverage on shares of Sol Gel Technologies in a research report on Monday, February 26th. They set a “market outperform” rating and a $20.00 target price on the stock. Finally, BMO Capital Markets started coverage on shares of Sol Gel Technologies in a research report on Monday, February 26th. They set an “outperform” rating and a $18.00 target price on the stock.

Shares of Sol Gel Technologies opened at $9.50 on Friday, according to MarketBeat Ratings. Sol Gel Technologies has a 12-month low of $8.70 and a 12-month high of $8.70.

A number of institutional investors have recently bought and sold shares of the stock. Point72 Asset Management L.P. purchased a new stake in Sol Gel Technologies in the 1st quarter worth about $103,000. DAFNA Capital Management LLC purchased a new stake in Sol Gel Technologies in the 1st quarter worth about $361,000. Guggenheim Capital LLC purchased a new stake in Sol Gel Technologies in the 1st quarter worth about $1,073,000. Nexthera Capital LP purchased a new stake in Sol Gel Technologies in the 1st quarter worth about $5,334,000. Finally, Delek Group Ltd. purchased a new stake in Sol Gel Technologies in the 1st quarter worth about $10,703,000. 4.97% of the stock is currently owned by institutional investors.

About Sol Gel Technologies

Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea.

Receive News & Ratings for Sol Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply